[01] Burcu Dirim, Department of Ophthalmology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. [02] Selam Yekta Sendul, Department of Ophthalmology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. [03] Semra Tiryaki Demir, Department of Ophthalmology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. [04] Ali Olgun, Department of Ophthalmology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. [05] Dilek Guven, Department of Ophthalmology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.

This retrospective study is designed to examine the results of photodynamic therapy (PDT) in our cases and compare our results with those of the previous studies. The data was collected from the files of 36 patients on whom PDT had been performed in the Retina Unit of the Ophthalmology Clinic of our Hospital. In the study group, gender, age, baseline best corrected visual acuity (BCVA), lesion types, mean PDT numbers, number of cases on whom multiple PDT were performed, mean visual acuity (VA) difference and the number of cases in the VA change groups were evaluated. The results were compared in themselves and with other studies. Although statistically not significant, predominantly classic and occult lesions responded to PDT better than the other one. After the estimation of all cases, a statistically significant increase was found between baseline and final VA results. Also in cases with low baseline BCVA, the benefit from the treatment was more significant than the other group. As a result of this study, it has been concluded that PDT with Verteporfin is an effective and reliable treatment that preserves visual acuity in CNV secondary to AMD. Further, for decreasing the frequency of PDT, combined therapies are also commonly preferred at present.

Age-Related Macular Degeneration, Photodynamic Therapy, Verteporfin, Choroidal Neovascularization, Visual Acuity

[01] Miller JW, Schmidt U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a Phase I and II study. Arch Ophthalmol 1999; 117: 1177-87. [02] Friedman DS, O’Colmain BJ, Munoz B, et al. Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122: 564–72. [03] Lim L. S., Mitchell P., Seddon J. M., Holz F. G., Wong T. Y. Age-related macular degeneration. The Lancet. 2012; 379 (9827): 1728–1738. [04] Jager R. D., Mieler W. F., Miller J. W. Age-related macular degeneration. The New England Journal of Medicine. 2008; 358 (24): 2606–2617. [05] Kulkarni AD, Kupperman BD. Wet age-related macular degeneration. Adv Drug Deliv Rev 2005; 57 (14): 1994-2009. [06] Macular Photocoagulation Study Group. Subfoveal Neovascular Lesions in Age-Related Macular Degeneration. Archives of ophthalmology 1991; 109 (9): 1242. [07] Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials. Archives of ophthalmology 1999; 117 (10): 1329-45. [08] Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32: 375-413. [09] Stokkermans TJ. Treatment of age-related macular degeneration. Clin Eye Vis Care 2000; 12 (1-2): 15-35. [10] Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classical choroidal neovascularization. American journal of ophthalmology 2001; 131 (5): 541-60. [11] Effect of lesion size, visual acuity and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration. Treatment of age-related macular degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Groups. Am J Ophthalmol 2003; 136: 407-418. [12] Tano Y, Ophthalmic PDT Study Group Guidelines for PDT in Japan. Ophthalmology. 2008; 115 (3): 585–585. [13] Yılmaz G, Küçükerdönmez FE. Anjiogenez ve VEGF. Karaçorlu M, Karaçorlu SA, Özdemir H, eds. Göz Hastalıkları ve AntiVEGF Tedavi. İstanbul; 2010: 11-21. [14] Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drug Aging. 2007; 24 (8): 643-62. [15] Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341 (23): 309-315. [16] Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin ExpImmunol 2000; 121 (3): 458-465.